Ind-swift Laboratories Ltd. · NSE:INDSWFTLAB
Ind-swift Laboratories — Q1 FY21 Earnings Presentation
26 slides from Ind-swift Laboratories's earnings presentation, Jul 31, 2020
Slide 1: Exchange filing cover letter
Ind-Swift Laboratories Limited : (A Recognised Export House) x Z Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101 es ea Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294 Ind-Switt E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
Slide 2: Investor Presentation Q1FY21
Ind-Swift Laboratories Limited Investor Presentation Q1FY21 1
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Ind-Swift Laboratories Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Contents
Contents Q1FY21 Performance & 01 Highlights Company 02 Overview Industry Outlook & 03 Growth Strategy Historical 04 Financials 3
Slide 5: Q1FY21 Performance & Highlights
Q1FY21 Performance & Highlights
Slide 6: Standalone Financial highlights – Q1FY21
Standalone Financial highlights – Q1FY21 Rs cr Revenue EBITDA 12.3% 13.9% 187 210 43 49 Q1FY20 Q1FY21 Q1FY20 Q1FY21 PAT Cash Profit 60.0% -8 4 15 24 Q1FY20 Q1FY21 Q1FY20 Q1FY21 5
Slide 7: Standalone Profit & loss statement – Q1FY21
Standalone Profit & loss statement – Q1FY21 Rs Cr Q1FY21 Q1FY20 % Change Net Sales 210 187 12.3% Cost of Raw Material 106 89 Gross Profit 104 98 6.5% Gross Profit margin 49.5% 52.2% Employee Benefit Expense 22 23 Other Expenses 33 32 Total Operating Expenses 55 55 EBITDA 49 43 13.9% EBITDA margin 23
Slide 8: Company Overview
Company Overview
Slide 9: A leading API player
A leading API player 788 cr 22.6% 280+ 7-8 years 70+ Revenue EBITDA Margin Customers Retention period for Countries with FY20 FY20 top 10 customers product presence 32 18 2500+ 690 KL 696 MT Molecules Therapeutic Employees Reactor capacity Bulk drug capacity Categories R&D Infrastructure With Strong
Slide 10: Corporate History
Corporate History 2005 2007 2011 Second Plant at Jammu USFDA site USFDA site 2015 2018 established approval (total DMF approval filed: 9) (total DMF 1995 1998 filed: 20) USFDA site USFDA site Incorporated First Plant at by Ind Swift Derabassi 2006 approval approval 2010 Limited with commences $10m G
Slide 11: Key Products
Broad portfolio across multiple therapeutic areas FY20 Standalone Number of Product Indication Revenue FY20 Revenue Share Clients (Rs Cr) Clarithromycin Anti-infective 155 239 Fexofenadine Allergic rhinitis 62 114 22% Atorvastatin Hypercholesterolaemia 85 103 32% Clopidogrel Atherothrombotic events
Slide 12: Geographical Revenue Breakup
.. With significant market share in key products Global Market Share by Volume FY20 8% Clarithromycin 25% Geographical Revenue Breakup Fexofenadine 20-25% 30% 19% Atorvastatin 10% Key Products Clopidogrel 15-18% Ezetimibe 8% Nitazoxanide 40% 15% 19% Ivabradine 25% 9% Not depicted in the chart above
Slide 13: Key Highlights
Growing CRAMS opportunities ▪ Involved in pharmaceutical CRAMS applications for several years and recently ventured into CRAMS for specialty chemicals in the display technology space ▪ Plans to capitalize on reducing dependency on China for supply of such intermediates ▪ Key features of CRAMS for th
Slide 14: Derabassi Facility
High quality manufacturing facilities Reaction Capacity: 510KL Over 33 acres 22 cGMP plants Zero discharge Derabassi Facility ▪ GMP pilot plant suitable for Advanced Intermediates, key starting material required for manufacturing API. ▪ Dedicated facility for Oncology products with world-class Isola
Slide 15: Mohali R&D Overview
Dedicated R&D infrastructure with strong capabilities 11 products in pipeline with 4 Mohali R&D Center included to commercialize by FY22 474 DMFs 119 scientists Mohali R&D Overview • State-of-the-art R&D campus over 2 acres • 147 highly qualified R&D employees including 119 scientists, approved by D
Slide 16: Long standing relationship with key customers
Long standing relationship with key customers Proudly maintaining long standing relationships with multiple clients for 10+ years 15
Slide 17: Represented by a professional team
Represented by a professional team Mr. Nav Rattan Munjal Dr. Lalit Wadhwa Mr. Vijay Kumar Chairman & Managing Director Chief Operating Officer Director of Marketing • Responsible for overall corporate strategy • Responsible for overall operations • Responsible for marketing operations (except • Scie
Slide 18: Industry Outlook & Growth Strategy
Industry Outlook & Growth Strategy
Slide 19: Large, attractive and growing API market
Large, attractive and growing API market Worldwide Generic Drug Sales ($Bn) As branded drugs become off-patent, exports CAGR – 6.1% of generics to US will rise 101 106 90 95 79 84 Affordability of drugs will rise due to sustained growth in incomes and in insurance coverage Population growth at aroun
Slide 20: With government led initiatives
With government led initiatives Reducing Dependency on China • China is the leader in API manufacturing with over 70% of raw materials for global API production being imported from China • With India’s increasing cost competitiveness the Govt. plans to reduce import dependency on China by encouragin
Slide 21: Growth strategy to tap into opportunities
Growth strategy to tap into opportunities 1 2 Existing and New Product Pipeline New Markets ▪ Stable revenue stream on the back of deep ▪ Increase revenue share from higher margin relationship with long lasting customers regulated markets ▪ Continued growth in volume ▪ Strengthening marketing teams
Slide 22: Historical Financials
Historical Financials
Slide 23: Standalone financial highlights
Standalone financial highlights Revenue (Rs Cr) EBITDA & EBITDA Margin (Rs Cr) 771 788 19.4% 22.3% 22.6% 750 172 178 145 FY18 FY19 FY20 FY18 FY19 FY20 PBT (Rs Cr) Cash Profit (Rs Cr) 31 143 105 -24 -20 69 FY18 FY19 FY20 FY18 FY19 FY20 22
Slide 24: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement Rs Cr FY20 FY19 FY18 Net Sales 788 771 750 Cost of Raw Material 379 379 375 Gross Profit 409 392 375 Gross Profit margin 51.9% 50.8% 50.0% Employee Benefit Expense 100 95 89 Other Expenses 131 124 140 Total Operating Expenses 231 220 229 EBITDA 178 172 145 EBITDA m
Slide 25: Standalone Balance Sheet
Standalone Balance Sheet (Rs. Cr) Mar-20 Mar-19 (Rs. Cr) Mar-20 Mar-19 EQUITY & LIABILITY ASSETS Share Capital 60 48 Non-Current Assets Total Reserves 585 542 Fixed Assets incl CWIP & intangible 854 933 Shareholder's Funds 645 590 Investment in subsidiary 26 26 Long-Term Borrowings Financial Assets
Slide 26: Thank You
Thank You Ind-Swift Laboratories Limited Gagan Aggarwal - CFO gagan@indswiftlabs.com Pardeep Verma – AVP – Corporate Affairs and Company Secretary pardeep.verma@indswiftlabs.com Pareto Capital (Investor Relations) Pooja Dokania pooja.dokania@paretocapital.in Rishav Das rishav.das@paretocapital.in
Ind-Swift Laboratories — Q1 FY21 Earnings Presentation on 6ix